Abhishek Das - research works

Our study evaluates the outcomes, adverse effects and challenges of IAC in the management of RB in an Indian cohort.

Drugs used were melphalan (5/7.5 mg) and topotecan (1/2 mg) (n=14) or melphalan (5 mg) alone (n=3) or triple therapy, which included carboplatin (30 mg) along with these drugs (n=4).

Complete regression of the main tumor was seen in 12 eyes (57%) and partial regression in 9 eyes (43%).

240 (78.43%) had unilateral macular tumours, while 45 (14.71%) had bilateral macular tumours.

Visual impairment and legal blindness were noted in only 27.59% and 0.05% of patients without macular tumours.

Three patients had motor and speech delay.

Out of 120 patients with bilateral tumour, 45 successfully underwent occlusion therapy.

Out of the 17 patients, 11 were diagnosed with unilateral RB and 6 were diagnosed with bilateral RB.

The mean age at the time of diagnosis was 19.8 months.

The mean interval between the first symptom and presentation was 6.5 months.

Each eye received a mean of 1.5 IAC sessions (median: 1 session; range: 1-3 sessions).